Evaluation of the Efficacity of Lanreotide LP 90 mg to Minimized the Lymphorrhea Post Axillary Lymphadenectomy in Breast Cancer
Patients will be recruited among patient refered to our department for a breast cancer and
needing an axillary dissection. Enrolled patients will have an injection of Lanreotide or
placebo the day before surgery when they arrive in their room. The quantity of lymph in
axillary drain will by daily noted until day 4. The patient will be evaluated at D15, D30
and M6 for pain, lymphocele and adverse events.
Data will be compared in the 2 groups.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Quantity of lymph collected by the drain
D4 post operativly
Yves Aubard, MD, PhD
University Hospital, Limoges
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)